GDT

Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

Retrieved on: 
Friday, March 1, 2024

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as the second clinical trial site in the Phase 1 Deltacel-01 trial evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with non-small cell lung cancer (NSCLC).

Key Points: 
  • Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as the second clinical trial site in the Phase 1 Deltacel-01 trial evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with non-small cell lung cancer (NSCLC).
  • “Virginia Oncology Associates is known for its excellence in oncology-focused research and patient care, and we are delighted to add them as the second Deltacel-01 clinical trial site.
  • The site initiation process at Virginia Oncology Associates has been completed and patient enrollment is expected to begin in April, following receipt of preliminary results from the first three-patient cohort in Deltacel-01.
  • Kiromic also announces that the third patient in Deltacel-01 completed treatment at the Beverly Hills Cancer Center on February 21.

General Datatech (GDT) Adds Industry Veteran to Executive Leadership Team

Retrieved on: 
Wednesday, December 27, 2023

Haughey brings an impressive portfolio of experience to GDT, including 20 years of public accounting and management consulting and 10 years in the private sector.

Key Points: 
  • Haughey brings an impressive portfolio of experience to GDT, including 20 years of public accounting and management consulting and 10 years in the private sector.
  • In his most recent leadership role at Riveron Consulting, LLC, Haughey helped drive efficiencies, operational changes, and data-driven reporting that led to top-line and bottom-line growth for his clients.
  • "It's an incredible time to be a part of GDT," adds Haughey.
  • "The recent Great Place to Work™ certification in both the U.S. and India is just one example of GDT's workplace culture and industry reputation.

General Datatech (GDT) is Great Place to Work® Certified™ in US and India

Retrieved on: 
Tuesday, December 12, 2023

DALLAS, Dec. 12, 2023 /PRNewswire/ -- Global IT solutions provider General Datatech (GDT) is proud to announce that both their U.S. and India offices are Great Place to Work® Certified™.

Key Points: 
  • DALLAS, Dec. 12, 2023 /PRNewswire/ -- Global IT solutions provider General Datatech (GDT) is proud to announce that both their U.S. and India offices are Great Place to Work® Certified™.
  • Great Place To Work Certification recognizes employers who create an outstanding employee experience.
  • Ninety one percent of employees at GDT say it's a great place to work compared to 57% of employees at a typical U.S.-based company.
  • The Great Place to Work Trust Index Survey measures individual employee experiences on five dimensions of a high-trust company culture.

Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center

Retrieved on: 
Thursday, November 9, 2023

Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the Deltacel™ Phase 1 Clinical Trial is now recruiting patients at the Beverly Hills Cancer Center (BHCC).

Key Points: 
  • Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the Deltacel™ Phase 1 Clinical Trial is now recruiting patients at the Beverly Hills Cancer Center (BHCC).
  • The study will evaluate Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with metastatic non-small cell lung cancer (NSCLC).
  • The Company continues to engage additional clinical trial sites across the U.S, and will provide updates as additional sites are activated, and as patient recruitment starts at those locations.
  • “We are delighted to announce the start of patient recruitment in our first clinical trial, and we look forward to working with BHCC and the other prestigious trial sites we will be activating across the U.S.

Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement

Retrieved on: 
Monday, October 23, 2023

Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the execution of a clinical trial agreement with Beverly Hills Cancer Center (BHCC) to conduct its Deltacel-01 Phase 1 Study.

Key Points: 
  • Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the execution of a clinical trial agreement with Beverly Hills Cancer Center (BHCC) to conduct its Deltacel-01 Phase 1 Study.
  • The collaboration between Kiromic BioPharma and BHCC underscores the shared commitment between the two organizations to advance the fight against cancer through innovative therapeutic approaches.
  • “The clinical trial agreement is a momentous first step in the development of this important treatment.
  • Lung cancer is by far the leading cause of cancer death in the U.S., accounting for about 1 in 5 of all cancer deaths.

GDT Achieves Fortinet Engage Preferred Services Partner Designation

Retrieved on: 
Thursday, October 19, 2023

The Engage Preferred Services Partner (EPSP) designation within Fortinet company's Engage Partner Program demonstrates GDT's proven expertise in deploying, operating, and maintaining end-to-end security solutions.

Key Points: 
  • The Engage Preferred Services Partner (EPSP) designation within Fortinet company's Engage Partner Program demonstrates GDT's proven expertise in deploying, operating, and maintaining end-to-end security solutions.
  • "GDT is thrilled to build on our security and networking expertise as a Fortinet Preferred Services Partner.
  • To achieve the Fortinet Preferred Services Partner designation, GDT demonstrated a high level of service quality and best practices for Fortinet deployment and operations within our client base.
  • Additionally, GDT invested heavily in certifications and process alignment with Fortinet to enable close collaboration with Fortinet professional services and regional sales teams allowing GDT to provide reciprocal consultancy to Fortinet.

DARIGOLD COMPLETES FIRST OFFERING THROUGH GLOBAL DAIRY TRADE PLATFORM

Retrieved on: 
Thursday, July 6, 2023

SEATTLE, July 6, 2023 /PRNewswire/ -- Darigold, Inc., the Seattle-based farmer-owned dairy co-op, has joined the Global Dairy Trade (GDT) platform and has completed its first product offering through GDT Events. Through the offering, initiated on July 4 as part of GDT Trading Event 335, Darigold offered two skim milk powder products and one buttermilk powder product.

Key Points: 
  • SEATTLE, July 6, 2023 /PRNewswire/ -- Darigold, Inc., the Seattle-based farmer-owned dairy co-op, has joined the Global Dairy Trade (GDT) platform and has completed its first product offering through GDT Events.
  • "But the growth opportunities in dairy are more robust in global markets, and our co-op is uniquely positioned to leverage this opportunity.
  • While we're already a top-tier dairy producer in the United States, there's an opportunity for us to transform Darigold into a global leader in the category as well.
  • Eric Hansen, CEO of Global Diary Trade, said, "Our three-year strategic plan includes a focus on improving the global supply of dairy products.

EDAN Announces Integration with PointClickCare for Better Senior Primary Care

Retrieved on: 
Wednesday, May 3, 2023

SAN DIEGO, May 3, 2023 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a leading healthcare company and medical devices manufacturer, recently announced its integration with PointClickCare through its newly launched informatics solutions Allink.

Key Points: 
  • SAN DIEGO, May 3, 2023 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a leading healthcare company and medical devices manufacturer, recently announced its integration with PointClickCare through its newly launched informatics solutions Allink.
  • The solution is now available on PointCareClick Marketplace , aiming to provide an efficient healthcare workflow that is far less labor-intensive and could free the caregivers for better patient care.
  • Vital signs monitoring, as a must-have for monitoring seniors' most essential bodily functions, could be time consumption and human error involved.
  • "Partnering with PointClickCare, the top long-term care software provider in North America, would be a great chance for us to dive deep into senior care, and even the whole out-of-hospital ecosystem."

Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer

Retrieved on: 
Monday, May 1, 2023

Notably, Deltacel does not require the use of any viral vector as many other cell therapies do, which, among other advantages, allows for reduced manufacturing costs.

Key Points: 
  • Notably, Deltacel does not require the use of any viral vector as many other cell therapies do, which, among other advantages, allows for reduced manufacturing costs.
  • Lung cancer is by far the leading cause of cancer death in the US, accounting for about 1 in 5 of all cancer deaths.
  • “Receiving the authorization from the FDA to administer Deltacel to patients enables us to advance our GDT therapy candidate into the clinic.
  • “We are in the process of activating clinical trial sites, and we look forward to providing updates on our progress.”

TC BioPharm Increases Allogeneic Car and Partnering Focus for Advancement of TCB-008

Retrieved on: 
Wednesday, April 26, 2023

EDINBURGH, Scotland, April 26, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company today laid out a fundamental shift in the ongoing development and manufacture of its lead product TCB-008, an allogeneic gamma-delta T cell therapies for cancer, and the Company's CAR modified gamma-delta T cell.

Key Points: 
  • A collaborative integration of TC BioPharm's primary asset, TCB-008, will further enable the Company to expand operations into CAR Therapy with a focus on binder B7H3 for the treatment of ovarian cancer.
  • The shift should enable the company to maximize the potential of its therapies and increase the value of the assets and the company.
  • TCBP will increase the focus on the CAR program, looking to shorten the timeline to completing a pre-clinical package and pursuing a US Phase I trial.
  • We firmly believe in the potential of TCB-008 and we continue to position the Company to be more economically efficient."